Association Between Quantity of Liver Fat and Cardiovascular Risk in Patients With Nonalcoholic Fatty Liver Disease Independent of Nonalcoholic Steatohepatitis

Nonalcoholic fatty liver disease and cardiovascular risk

“…Overall survival was reduced in subjects with NASH compared to the general population due to increased mortality by cardiovascular disease. Importantly in this study, only subjects with NASH had significantly reduced survival [9][10][11] .…”

“…In patients with NAFLD high proton-density-fat-fraction on MRI was a predictor of metabolic syndrome and increased cardiovascular risk [10] .…”

“…Quantity of liver fat has been reported to be predictive of metabolic syndrome and CVD risk. In a recent study Loomba et al [10] quantified liver fat in patients with NAFLD and controls using a magnetic resonance imaging and measuring proton-density-fat-fraction (MRI-PDFF).…”

Can FIB4 and NAFLD fibrosis scores help endocrinologists refer patients with non-alcoholic fat liver disease to a hepatologist?

“…Diagnosis of this condition will therefore be more important for endocrinologists and for public health systems (6) as it may increase direct and indirect health costs (7), generate referrals to specialists (12) and alter morbidity and mortality of patients, due to increased risk of cardiovascular events (25,26), and progression of the liver disease (27). Hepatocellular carcinoma rates are expected to increase in the future (28,29), and NAFLD is predicted to be the main reason for liver transplants in 2020 (27).…”

Cardiovascular risk assessment in the treatment of nonalcoholic steatohepatitis: a secondary analysis of the MOZART trial

“…Furthermore, there may be a role for CAC scores in assessing long-term, longitudinal cardiovascular risk among patients with NASH [Kim et al 2012;Budoff et al 2013]. Other imaging modalities to assess cardiovascular risk, such as cardiac MRI or quantitative ultrasound [Lin et al 2014] to quantify hepatic steatosis, which has been associated with cardiovascular disease [Arulanandan et al 2015], may be utilized in future trials. Measures of vascular and endothelial dysfunction, such as the ankle-brachial index, measures of flow-mediated dilation and carotid intima-media thickness [Sookoian and Pirola, 2008;Kozakova et al 2012], may be potential cardiovascular endpoints in future NASH trials.…”